Pharmaceuticals
Jadeite Medicines Receives Orphan Drug Designation for Odevixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) from the Ministry of Health, Labour and Welfare of Japan and will also initiate Phase 3 Trial of Odevixibat in PFIC in Japan
TOKYO, June 20, 2023 /PRNewswire/ -- Jadeite Medicines Inc., (Jadeite Medicines) a clinical stage biopharmaceutical company headquartered inTokyo, Japan (President & CEO, Eiichi Takahashi) has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of...
2023-06-21 09:00
2560
Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA )
SHANGHAI, June 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") made presentations on data from the NeflgArd Phase 3 Study at the European Renal...
2023-06-21 08:15
4128
Telix Urology Innovation Showcase to be held at The Yale Club, New York City
MELBOURNE, Australia and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company's briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.3...
2023-06-21 06:31
2415
Clarity commences COMBAT theranostic prostate cancer trial in the US
SYDNEY, June 20, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce it has commenced its64C...
2023-06-20 21:03
1810
Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other autoimmune diseases, announced the preliminary phase I data of LP-003 ...
2023-06-20 21:00
1664
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies a...
2023-06-20 18:30
4557
Curocell announced encouraging updates on the next-generation anti-CD19 CAR-T, Anbalcabtagene-autoleucel at International Conference on Malignant Lymphoma (ICML) 2023
* 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphoma * Durable complete response was measured-68% at 1 month, 61% at 3 months, and 60% at 6 months respectively. DAEJEO...
2023-06-20 08:01
868
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"; stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the adv...
2023-06-19 21:29
3643
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients
ALHAMBRA, Calif., June 19, 2023 /PRNewswire/ -- Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, today announced topline data from the company's Phase1b clinical trial for AG-80308, a first-in-class, formyl peptide re...
2023-06-19 16:00
1448
Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients
- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its use as a treatment for heart transplant rejection and prevention of rejection1 - DUBLIN, June 19, 2023 /PR...
2023-06-19 06:30
2326
The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug
- Professor Heungjeong Woo of Hallym University College of Medicine, announced the result of Xafty's clinical study at Emerging Science Session of the American Society for Microbiology (ASM) Microbe 2023 - Dr. Jo White evaluated Xafty's clinical results as "The birth of Penicillin of Antivirals"...
2023-06-18 03:30
3650
The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer
NANJING, China, June 16, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the phase I/II clinical trial application for LBL-033, an anti-MUC16/CD3 bispecific antibody, for the treatment of ovarian cancer and other m...
2023-06-16 22:01
2079
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
HONG KONG, June 16, 2023 /PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised nearlyUS$ 150 million through the transfer of approximately 24% of its equity interest to Temasek,...
2023-06-16 14:20
5520
Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer
SHANGHAI, June 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, today announced that Dr.Mike Berry has been appointed Chief Techno...
2023-06-16 07:45
2477
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
* Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign * Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immu...
2023-06-16 06:05
2532
Qiming Venture Partners fosters life science, medical and healthcare talent development First healthcare catalyst program starts recruiting in Hong Kong universities
SHANGHAI and HONG KONG, June 15, 2023 /PRNewswire/ -- Qiming Venture Partners ("Qiming") today launched its first "Catalyst: Qiming Healthcare Summer Program 2023" for universities inHong Kong, fostering talent development and cross-border integration for the life science, medical and healthcare ...
2023-06-15 22:58
3028
Mabwell Announces the U.S. FDA approval of 9MW3811 for IND
SHANGHAI, June 15, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the entire value chain of the pharmaceutical industry, announced the clinical trial application of its self-developed 9MW3811 injection for idiopathic pulmonary fibrosis has been approved by ...
2023-06-15 21:00
1964
Mabwell Publishes the Preclinical Study Results on Its Nectin-4 Targeting ADC in A Well-known AACR Journal
SHANGHAI, June 15, 2023 /PRNewswire/ -- Recently, the preclinical study results of 9MW2821, the first domestically developed Nectin-4-targeting ADC by Mabwell, were published in the renowned journal "Molecular Cancer Therapeutics" under the American Association for Cancer Research (AACR). The pap...
2023-06-15 21:00
1966
China Jo-Jo Drugstores Reports Fiscal Year 2023 Financial Results
HANGZHOU, China, June 15, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced its finan...
2023-06-15 21:00
4429
Addentax Group Corp. in Advanced Talks to Acquire Partial Stake in RMB 6 Billion-Valued Recombinant Protein Drugs and Antibody Drugs Bio-pharmaceutical Company, Shanghai Bao Pharmaceutical Company Limited
SHENZHEN, China, June 15, 2023 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management and subleasing, and epidemic prevention supplies, today announced that it is ...
2023-06-15 20:00
3860
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 282 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 277 media titles]
2024-04-19 13:25
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
3869
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3823
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3088
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3026